LON:MPH Mereo BioPharma Group plc (MPH.L) (MPH) Share Price, News & Analysis GBX 26.50 -0.50 (-1.85%) (As of 12/17/2020) Add Compare Share Share Today's Range 26▼ 26.5050-Day Range 26.50▼ 26.5052-Week Range 13▼ 60Volume49,264 shsAverage Volume333,975 shsMarket Capitalization£89.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Mereo BioPharma Group plc (MPH.L) alerts: Email Address Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Mereo BioPharma Group plc (MPH.L) Stock (LON:MPH)Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.Read More MPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MPH Stock News HeadlinesJuly 26 at 5:32 AM | americanbankingnews.comMereo BioPharma Group plc (MPH.L) (LON:MPH) Shares Pass Below 50-Day Moving Average of $26.50July 19, 2024 | finance.yahoo.comMereo BioPharma Group plc (MAH0.F)July 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)April 14, 2024 | morningstar.comMereo BioPharma Group PLC ADR MREOFebruary 24, 2024 | msn.comMereo BioPharma Group plc - Depositary Receipt () (MREO) Price Target Increased by 17.65% to 5.10February 23, 2024 | benzinga.comMereo BioPharma Group Stock (NASDAQ:MREO), Insider Trading ActivityFebruary 22, 2024 | wsj.comMereo BioPharma Group PLC ADRJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.January 8, 2024 | msn.comMereo BioPharma provides update on pipeline progress, reaffirms cash runway guidanceJanuary 8, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Mereo Biopharma Group Plc (MREO)January 8, 2024 | markets.businessinsider.comMereo BioPharma Provides Update on Pipeline Progress and Corporate DevelopmentsDecember 13, 2023 | seekingalpha.comMereo BioPharma: Lagging Stock Despite Positive DataOctober 23, 2023 | markets.businessinsider.comMereo BioPharma Reports on Recent Program Developments and Provides Financial UpdateJune 14, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Buy Rating for Mereo Biopharma Group Plc (MREO)June 6, 2023 | msn.comUltragenyx, Mereo shares gain after positive results from study of bone disorder treatmentJune 6, 2023 | msn.comUltragenyx, Mereo gain on Phase 2 data for bone disorder therapyMay 31, 2023 | technews.tmcnet.comMereo BioPharma to Present at the Jefferies Healthcare ConferenceSee More Headlines Receive MPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/29/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:MPH CUSIPN/A CIKN/A Webmereobiopharma.com Phone44 33 3023 7300FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio164.26 Current Ratio2.98 Quick Ratio2.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 17.12 per share Price / Cash Flow1.55 Book ValueGBX 7.20 per share Price / Book3.68Miscellaneous Outstanding Shares338,713,984Free FloatN/AMarket Cap£89.76 million OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Denise Scots-Knight (Age 61)Co-Founder, CEO & Exec. Director Comp: $751.37kMr. Charles Sermon (Age 51)Co-Founder, Gen. Counsel & Company Sec. Comp: $545.68kDr. Alastair MacKinnon (Age 50)Co-Founder & Chief Medical Officer Comp: $540.12kMr. John Richard (Age 63)Co-Founder & Head of Corp. Devel. Comp: $512.99kMr. Michael Stephen Wyzga MBA (Age 65)Interim CFO & Exec. Director Comp: $27.59kMs. Alexandra Hughes-Wilson (Age 49)Head of Patient Access & Commercial Planning Comp: $265.93kMs. Jill Henrich (Age 57)US Site Head & Sr. VP of Regulatory Affairs Comp: $286.93kDr. John A. Lewicki (Age 68)Chief Scientific Officer Dr. Fiona BorHead of Intellectual PropertyMr. Ian HodgsonHead of Clinical OperationsMore ExecutivesKey CompetitorsOxford BiomedicaLON:OXBHorizon Discovery Group plc (HZD.L)LON:HZDAvacta GroupLON:AVCTVerona Pharma plc (VRP.L)LON:VRPBioventixLON:BVXPView All Competitors MPH Stock Analysis - Frequently Asked Questions How have MPH shares performed this year? Mereo BioPharma Group plc (MPH.L)'s stock was trading at GBX 26.50 at the beginning of 2024. Since then, MPH stock has increased by 0.0% and is now trading at GBX 26.50. View the best growth stocks for 2024 here. How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter? Mereo BioPharma Group plc (MPH.L) (LON:MPH) issued its earnings results on Tuesday, September, 29th. The company reported ($105.00) EPS for the quarter. How do I buy shares of Mereo BioPharma Group plc (MPH.L)? Shares of MPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group plc (MPH.L) investors own include Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Inovio Pharmaceuticals (INO), Micron Technology (MU), Tesla (TSLA) and Amgen (AMGN). This page (LON:MPH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc (MPH.L) Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group plc (MPH.L) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.